Lurbinectedin (Zepzelca) — CPB 0978 | AETNA Coverage Update

Aetna modified CPB 0978 for lurbinectedin (Zepzelca), effective December 10, 2025. Here's what billing teams need to know before submitting claims under this updated coverage policy.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0978 Aetna system governing lurbinectedin (Zepzelca) coverage for commercial medical plan members. The policy sets medical necessity criteria for HCPCS code J9223 (injection, lurbinectedin, 0.1 mg), billed alongside chemotherapy administration codes CPT 96413 and CPT 96415. Coverage is limited to small cell lung cancer (SCLC) only — all other indications are experimental. Every claim requires precertification before treatment starts.

Quick-Reference Table

Aetna Lurbinectedin Coverage Criteria and Medical Necessity Requirements 2025

The Aetna lurbinectedin coverage policy under CPB 0978 covers Zepzelca as a single agent for subsequent treatment of small cell lung cancer. Aetna will not approve lurbinectedin as a first-line treatment. This is strictly a second-line-and-beyond drug under this policy.

To meet medical necessity, the member must fall into one of three clinical scenarios. First, relapse after complete response, partial response, or stable disease on initial treatment. Second, primary progressive disease. Third, metastatic SCLC following disease progression on or after platinum-based chemotherapy — which means prior exposure to carboplatin (J9045), cisplatin (J9060), or oxaliplatin (J9263) is a documented baseline for many patients in this category.

Prior authorization is required for every Aetna participating provider and member in an applicable plan design. Call (866) 752-7021 or fax the precertification request to (888) 267-3277. Use the Specialty Pharmacy Precertification SMN forms available through Aetna's provider portal. There are no exceptions to this requirement — bill J9223 without an approved authorization and you will get a claim denial.

The prior authorization requirement applies to both initial treatment and reauthorization for continuation therapy. Don't assume an approved initial auth rolls forward automatically.

Aetna Lurbinectedin Exclusions and Non-Covered Indications

Aetna considers lurbinectedin (Zepzelca) experimental, investigational, or unproven for all indications outside of SCLC. That language is broad and intentional.

The real issue here: lurbinectedin has been studied in other tumor types — endometrial cancer, breast cancer, Ewing's sarcoma, and others. None of those indications clear the bar under this coverage policy. If your oncologist is using Zepzelca off-label for anything other than SCLC, Aetna will deny it. Document the diagnosis carefully. ICD-10 codes from the C34.xx range confirm SCLC; non-small cell lung cancer codes from the same C34 family do not.

The policy explicitly flags this: C34.xx codes are covered for SCLC only, not for non-small cell lung cancer. If a coder defaults to an unspecified C34 code without histology confirmation, expect a denial. Get the pathology report in the chart before you submit.

Coverage Indications at a Glance

Aetna Lurbinectedin Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Lurbinectedin Under CPB 0978

HCPCS Codes — Covered When Selection Criteria Are Met

CPT Codes — Chemotherapy Administration (Related to CPB 0978)

HCPCS Codes — Related (Platinum-Based Chemotherapy Context)

These codes appear in the policy as related codes. They're not covered under CPB 0978 for lurbinectedin itself, but they document prior platinum-based regimens that establish medical necessity eligibility for the metastatic/progression criterion.

Key ICD-10-CM Diagnosis Codes

Aetna's policy includes 213 ICD-10-CM codes in the C34.xx range. Coverage applies only when SCLC histology is confirmed. The same codes are explicitly excluded for non-small cell lung cancer. Below is a representative sample of the covered range:

The full list runs to 213 codes covering detailed site, laterality, and encounter-type specificity within the C34 range. Pull the complete list from CPB 0978 directly when building your charge capture templates. The key rule for every code: histology documentation must confirm small cell. No SCLC confirmation, no coverage.